摘要
肝细胞癌(HCC)是最常见的原发性肝癌,尽管已有相对成熟且系统的治疗方案,但总体治疗效果尚不令人满意。针对晚期HCC患者的治疗,除了酪氨酸激酶抑制剂外,免疫检查点抑制剂(ICIs)的使用日益广泛,并且取得了不错的效果。本文通过总结细胞毒性T淋巴细胞相关抗原4(CTLA-4)、程序性死亡受体1(PD-1)及其配体PD-L1抑制剂在晚期HCC治疗中的最新进展,以指导临床治疗和研究。
Hepatocellular carcinoma(HCC)is the most common primary liver cancer.Although there are relatively mature and systematic treatment regimens,the overall therapeutic effect of HCC is still unsatisfactory.In addition to tyrosine kinase inhibitors,immune checkpoint inhibitors(ICIs)have been widely used for advanced HCC patients and achieved good results.In this review,we summarize the latest progress of cytotoxic T lymphocyte-associated antigen 4(CTLA-4),programmed death receptor-1(PD-1)and programmed death receptor-1 ligand(PD-L1)inhibitors in the treatment of advanced HCC,aiming to guide the clinical treatment and research.
作者
王俊旗
徐锋
Wang Junqi;Xu Feng(Department of General Surgery,Shengjing Hospital of China Medical University,Shenyang 110004,China)
出处
《中华普通外科学文献（电子版）》
CAS
2021年第4期304-308,共5页
Chinese Archives of General Surgery(Electronic Edition)
基金
辽宁省自然科学基金项目(20180551193,2020-MS-181)
盛京医院345人才工程计划项目(40B)。
